What is the projected market valuation for the Cell And Gene Therapy Manufacturing Quality Control QC Market in 2035?

The projected market valuation for 2035 is 18.41 USD Billion. Read More

What was the overall market valuation for this sector in 2024?

The overall market valuation was 7.074 USD Billion in 2024. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 9.08%. Read More

Which companies are considered key players in the Cell And Gene Therapy Manufacturing Quality Control QC Market?

Key players include Lonza, Thermo Fisher Scientific, Merck KGaA, WuXi AppTec, Catalent, Boehringer Ingelheim, Samsung Biologics, Novartis, and GSK. Read More

What are the main segments of the market based on therapy type?

The main segments based on therapy type are Cell Therapy, valued at 9.5 USD Billion, and Gene Therapy, valued at 8.91 USD Billion. Read More

How does the market perform in terms of quality control methodology?

In terms of quality control methodology, In-Process Testing is projected to reach 6.5 USD Billion, while Release Testing is expected to reach 6.94 USD Billion. Read More

What are the anticipated valuations for the different quality control phases by 2035?

By 2035, Pre-Clinical Testing is expected to reach 3.8 USD Billion, Clinical Trials 6.5 USD Billion, and Commercial Production 8.11 USD Billion. Read More

Which application areas are driving growth in the market?

The application areas driving growth include Oncology, Genetic Disorders, Infectious Diseases, and Cardiovascular Diseases, with Cardiovascular Diseases projected to reach 8.91 USD Billion. Read More

What is the expected market performance for different end users in 2035?

In 2035, Pharmaceutical Companies are expected to reach 6.5 USD Billion, Biotechnology Companies 5.0 USD Billion, and Contract Manufacturing Organizations 6.941 USD Billion. Read More

How does the market's growth trajectory appear in comparison to previous years?

The market's growth trajectory appears robust, with a significant increase from 7.074 USD Billion in 2024 to a projected 18.41 USD Billion by 2035. Read More

Cell Gene Therapy Manufacturing Quality Control Market

Cell And Gene Therapy Manufacturing Quality Control QC Market Research Report: Size, Share, Trend Analysis By Therapy Type (Cell Therapy, Gene Therapy), By Quality Control Methodology (In-Process Testing, Final Product Testing, Release Testing), By Quality Control Phase (Pre-Clinical Testing, Clinical Trials, Commercial Production), By Applications Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases), By End Users (Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations (CMOs) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

9.08%

2024 Market Size

$ 7.07 Billion

2035 Market Size

$ 18.41 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/30365-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapy Type (USD Billion)
  1. 4.1.1 Cell Therapy
  2. 4.1.2 Gene Therapy
2. 4.2 Healthcare, BY Quality Control Methodology (USD Billion)
  1. 4.2.1 In-Process Testing
  2. 4.2.2 Final Product Testing
  3. 4.2.3 Release Testing
3. 4.3 Healthcare, BY Quality Control Phase (USD Billion)
  1. 4.3.1 Pre-Clinical Testing
  2. 4.3.2 Clinical Trials
  3. 4.3.3 Commercial Production
4. 4.4 Healthcare, BY Application Area (USD Billion)
  1. 4.4.1 Oncology
  2. 4.4.2 Genetic Disorders
  3. 4.4.3 Infectious Diseases
  4. 4.4.4 Cardiovascular Diseases
5. 4.5 Healthcare, BY End User (USD Billion)
  1. 4.5.1 Pharmaceutical Companies
  2. 4.5.2 Biotechnology Companies
  3. 4.5.3 Contract Manufacturing Organizations (CMOs)
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Lonza (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Thermo Fisher Scientific (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck KGaA (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 WuXi AppTec (CN)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Catalent (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Boehringer Ingelheim (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Samsung Biologics (KR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY THERAPY TYPE
4. 6.4 US MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
5. 6.5 US MARKET ANALYSIS BY QUALITY CONTROL PHASE
6. 6.6 US MARKET ANALYSIS BY APPLICATION AREA
7. 6.7 US MARKET ANALYSIS BY END USER
8. 6.8 CANADA MARKET ANALYSIS BY THERAPY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
10. 6.10 CANADA MARKET ANALYSIS BY QUALITY CONTROL PHASE
11. 6.11 CANADA MARKET ANALYSIS BY APPLICATION AREA
12. 6.12 CANADA MARKET ANALYSIS BY END USER
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY THERAPY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
16. 6.16 GERMANY MARKET ANALYSIS BY QUALITY CONTROL PHASE
17. 6.17 GERMANY MARKET ANALYSIS BY APPLICATION AREA
18. 6.18 GERMANY MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY THERAPY TYPE
20. 6.20 UK MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
21. 6.21 UK MARKET ANALYSIS BY QUALITY CONTROL PHASE
22. 6.22 UK MARKET ANALYSIS BY APPLICATION AREA
23. 6.23 UK MARKET ANALYSIS BY END USER
24. 6.24 FRANCE MARKET ANALYSIS BY THERAPY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
26. 6.26 FRANCE MARKET ANALYSIS BY QUALITY CONTROL PHASE
27. 6.27 FRANCE MARKET ANALYSIS BY APPLICATION AREA
28. 6.28 FRANCE MARKET ANALYSIS BY END USER
29. 6.29 RUSSIA MARKET ANALYSIS BY THERAPY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
31. 6.31 RUSSIA MARKET ANALYSIS BY QUALITY CONTROL PHASE
32. 6.32 RUSSIA MARKET ANALYSIS BY APPLICATION AREA
33. 6.33 RUSSIA MARKET ANALYSIS BY END USER
34. 6.34 ITALY MARKET ANALYSIS BY THERAPY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
36. 6.36 ITALY MARKET ANALYSIS BY QUALITY CONTROL PHASE
37. 6.37 ITALY MARKET ANALYSIS BY APPLICATION AREA
38. 6.38 ITALY MARKET ANALYSIS BY END USER
39. 6.39 SPAIN MARKET ANALYSIS BY THERAPY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
41. 6.41 SPAIN MARKET ANALYSIS BY QUALITY CONTROL PHASE
42. 6.42 SPAIN MARKET ANALYSIS BY APPLICATION AREA
43. 6.43 SPAIN MARKET ANALYSIS BY END USER
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY THERAPY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY QUALITY CONTROL PHASE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY APPLICATION AREA
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END USER
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY THERAPY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
52. 6.52 CHINA MARKET ANALYSIS BY QUALITY CONTROL PHASE
53. 6.53 CHINA MARKET ANALYSIS BY APPLICATION AREA
54. 6.54 CHINA MARKET ANALYSIS BY END USER
55. 6.55 INDIA MARKET ANALYSIS BY THERAPY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
57. 6.57 INDIA MARKET ANALYSIS BY QUALITY CONTROL PHASE
58. 6.58 INDIA MARKET ANALYSIS BY APPLICATION AREA
59. 6.59 INDIA MARKET ANALYSIS BY END USER
60. 6.60 JAPAN MARKET ANALYSIS BY THERAPY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
62. 6.62 JAPAN MARKET ANALYSIS BY QUALITY CONTROL PHASE
63. 6.63 JAPAN MARKET ANALYSIS BY APPLICATION AREA
64. 6.64 JAPAN MARKET ANALYSIS BY END USER
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY THERAPY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY QUALITY CONTROL PHASE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY APPLICATION AREA
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END USER
70. 6.70 MALAYSIA MARKET ANALYSIS BY THERAPY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
72. 6.72 MALAYSIA MARKET ANALYSIS BY QUALITY CONTROL PHASE
73. 6.73 MALAYSIA MARKET ANALYSIS BY APPLICATION AREA
74. 6.74 MALAYSIA MARKET ANALYSIS BY END USER
75. 6.75 THAILAND MARKET ANALYSIS BY THERAPY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
77. 6.77 THAILAND MARKET ANALYSIS BY QUALITY CONTROL PHASE
78. 6.78 THAILAND MARKET ANALYSIS BY APPLICATION AREA
79. 6.79 THAILAND MARKET ANALYSIS BY END USER
80. 6.80 INDONESIA MARKET ANALYSIS BY THERAPY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
82. 6.82 INDONESIA MARKET ANALYSIS BY QUALITY CONTROL PHASE
83. 6.83 INDONESIA MARKET ANALYSIS BY APPLICATION AREA
84. 6.84 INDONESIA MARKET ANALYSIS BY END USER
85. 6.85 REST OF APAC MARKET ANALYSIS BY THERAPY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
87. 6.87 REST OF APAC MARKET ANALYSIS BY QUALITY CONTROL PHASE
88. 6.88 REST OF APAC MARKET ANALYSIS BY APPLICATION AREA
89. 6.89 REST OF APAC MARKET ANALYSIS BY END USER
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY THERAPY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
93. 6.93 BRAZIL MARKET ANALYSIS BY QUALITY CONTROL PHASE
94. 6.94 BRAZIL MARKET ANALYSIS BY APPLICATION AREA
95. 6.95 BRAZIL MARKET ANALYSIS BY END USER
96. 6.96 MEXICO MARKET ANALYSIS BY THERAPY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
98. 6.98 MEXICO MARKET ANALYSIS BY QUALITY CONTROL PHASE
99. 6.99 MEXICO MARKET ANALYSIS BY APPLICATION AREA
100. 6.100 MEXICO MARKET ANALYSIS BY END USER
101. 6.101 ARGENTINA MARKET ANALYSIS BY THERAPY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
103. 6.103 ARGENTINA MARKET ANALYSIS BY QUALITY CONTROL PHASE
104. 6.104 ARGENTINA MARKET ANALYSIS BY APPLICATION AREA
105. 6.105 ARGENTINA MARKET ANALYSIS BY END USER
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY QUALITY CONTROL PHASE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION AREA
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY THERAPY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY QUALITY CONTROL PHASE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION AREA
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY THERAPY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY QUALITY CONTROL PHASE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION AREA
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER
122. 6.122 REST OF MEA MARKET ANALYSIS BY THERAPY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY QUALITY CONTROL METHODOLOGY
124. 6.124 REST OF MEA MARKET ANALYSIS BY QUALITY CONTROL PHASE
125. 6.125 REST OF MEA MARKET ANALYSIS BY APPLICATION AREA
126. 6.126 REST OF MEA MARKET ANALYSIS BY END USER
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY THERAPY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY THERAPY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY QUALITY CONTROL METHODOLOGY, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY QUALITY CONTROL METHODOLOGY, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY QUALITY CONTROL PHASE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY QUALITY CONTROL PHASE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY APPLICATION AREA, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY APPLICATION AREA, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY END USER, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.2.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.2.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.2.5 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.3.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.3.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.3.5 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.4.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.4.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.4.5 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.5.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.5.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.5.5 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.6.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.6.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.6.5 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.7.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.7.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.7.5 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.8.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.8.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.8.5 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.9.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.9.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.9.5 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.10.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.10.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.10.5 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.11.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.11.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.11.5 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.12.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.12.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.12.5 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.13.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.13.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.13.5 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.14.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.14.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.14.5 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.15.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.15.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.15.5 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.16.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.16.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.16.5 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.17.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.17.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.17.5 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.18.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.18.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.18.5 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.19.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.19.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.19.5 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.20.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.20.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.20.5 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.21.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.21.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.21.5 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.22.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.22.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.22.5 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.23.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.23.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.23.5 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.24.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.24.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.24.5 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.25.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.25.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.25.5 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.26.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.26.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.26.5 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.27.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.27.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.27.5 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.28.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.28.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.28.5 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.29.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.29.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.29.5 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY THERAPY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY QUALITY CONTROL METHODOLOGY, 2025-2035 (USD Billion)
  3. 7.30.3 BY QUALITY CONTROL PHASE, 2025-2035 (USD Billion)
  4. 7.30.4 BY APPLICATION AREA, 2025-2035 (USD Billion)
  5. 7.30.5 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Cell Gene Therapy Manufacturing Quality Control Market Segmentation

Cell Gene Therapy Manufacturing Quality Control Market By Therapy Type (USD Billion, 2025-2035)

Cell Therapy
Gene Therapy

Cell Gene Therapy Manufacturing Quality Control Market By Quality Control Methodology (USD Billion, 2025-2035)

In-Process Testing
Final Product Testing
Release Testing

Cell Gene Therapy Manufacturing Quality Control Market By Quality Control Phase (USD Billion, 2025-2035)

Pre-Clinical Testing
Clinical Trials
Commercial Production

Cell Gene Therapy Manufacturing Quality Control Market By Application Area (USD Billion, 2025-2035)

Oncology
Genetic Disorders
Infectious Diseases
Cardiovascular Diseases

Cell Gene Therapy Manufacturing Quality Control Market By End User (USD Billion, 2025-2035)

Cell Gene Therapy Manufacturing Quality Control Market Companies
Biotechnology Companies
Contract Manufacturing Organizations (CMOs)

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035